Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer's disease tau.

ABSTRACT:

Background

Augmenting the brain clearance of toxic oligomers with small molecule modulators constitutes a promising therapeutic concept against tau deposition. However, there has been no test of this concept in animal models of Alzheimer's disease (AD) with initiation at a late disease stage. Thus, we aimed to investigate the effects of interventional late-stage Anle138b treatment, which previously indicated great potential to inhibit oligomer accumulation by binding of pathological aggregates, on the metabolic decline in transgenic mice with established tauopathy in a longitudinal ¹⁸F-fluorodeoxyglucose positron emission tomography (FDG-PET) study.

Methods

Twelve transgenic mice expressing all six human tau isoforms (hTau) and ten controls were imaged by FDG-PET

SUBMITTER: Brendel M 

PROVIDER: S-EPMC6670231 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature